ORIC: Advancing late-stage cancer programs with strong safety profiles and robust funding through 2028
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases with upcoming data at ESMO. Both programs address large markets, are well-fund…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.